Lauren Walters
Medical · Royal Oak, MINPI 1780007971
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,253 and has fallen 91.1% since, to $202 in 2025. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$969
- Takeda Pharmaceuticals U.S.A., Inc.$728
- Sanofi$608
- Optinose US, Inc.$439
- CSL Behring$337
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,97299%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $1,468 |
| GSK | 76 | $969 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $728 |
| Sanofi | 25 | $608 |
| Optinose US, Inc. | 23 | $439 |
| CSL Behring | 16 | $337 |
| Pfizer | 15 | $262 |
| Regeneron Healthcare Solutions, Inc. | 10 | $255 |
| Amgen | 11 | $236 |
| Alk-abello, Inc | 12 | $212 |
| Novartis | 12 | $209 |
| Pharming Healthcare, Inc. | 10 | $206 |
| Teva Pharmaceuticals USA, Inc. | 9 | $199 |
| Boehringer Ingelheim | 8 | $173 |
| Kaleo, Inc. | 8 | $147 |
| LEO Pharma Inc. | 9 | $143 |
| Biocryst US Sales Co., LLC | 4 | $106 |
| AbbVie | 4 | $90 |
| Covis Pharma GmbH | 3 | $46 |
| Bio Products Laboratory USA, Inc. | 3 | $45 |
| Genentech USA, Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $23 |
| Organon | 2 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$236
How this compares
$7,053 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $31,336 |
| Spiriva RespimatTiotropium Bromide | 18 | $15,357 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $10,508 |
| XhanceFluticasone Propionate | 12 | $7,540 |
| DuleraMometasone/Formoterol | 18 | $6,018 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,884 |
| Azelastine Hcl | 104 | $2,546 |
| Montelukast Sodium | 214 | $2,322 |
| Fluticasone Propionate | 144 | $2,253 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,034 |
| Ipratropium Bromide | 13 | $368 |
| Levocetirizine Dihydrochloride | 16 | $150 |
| Omeprazole | 17 | $115 |
| Ammonium Lactate | 12 | $109 |
| Triamcinolone Acetonide | 25 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $969 | $41,84568 claims |
| Boehringer IngelheimSpiriva Respimat | $173 | $15,35718 claims |
| Optinose US, Inc.Xhance | $439 | $7,54012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.
Other medical in Royal Oak
- Robert DemeesterRoyal Oak$27K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.